AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04686500 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tidal volume measured by spirometer and DIBH surface from CT image
Description: The SOC DIBH CT scan will be transferred to Eclipse treatment planning system for treatment planning. Tidal volume measured by spirometer and DIBH surface from CT image will be used as a reference surface for patient treatment initial setup. CBCT will be acquired before each fractional treatment for the patient alignment before beam delivery.
Study NCT04513665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZW25
Description: ZW25 at 20mg/kg intravenously (IV) every two weeks.
Study NCT00853658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: Enalapril 10 mg film-coated tablet and administered orally.
Study NCT00853658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril 10 mg film-coated tablet and administered orally.
Study NCT00853658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 mg titrated to 300 mg film-coated tablet and administered orally.
Study NCT02460224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAG525
Description: LAG525 was administered via intravenous (i.v.) infusion
Study NCT02460224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 was administered via i.v. infusion
Study NCT00466765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brava Autologous Fat Transfer System
Description: Number of procedures is based on patient need
Study NCT01698229 — intervention group
Intervention type: OTHER
Intervention: Group 1
Description: Collecting a small amount of cerebrospinal fluid (5 mL) from healthy children, ages 2 yrs - 8 yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
Study NCT03334227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Flow nasal cannula (HFNC)
Description: The patient will receive HFNC adjusted for SatO2 > 92% and with, at least, 30 liters of total flow.
Study NCT01894542 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cod protein from presscake
Description: 6g protein per day for 8wk
Study NCT01894542 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cod protein from presscake + stickwater
Description: 6 g protein per day for 8 wk
Study NCT01894542 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study NCT03591666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib p.o. qd
Study NCT04014413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal microbiota transplantation
Study NCT02500095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Concomitant saline during fasting
Study NCT02500095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegvisomant
Description: Concomitant Growth hormone receptor blockade with Pegvisomant during fasting
Study NCT02952144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lixelle® treatment
Description: The treatment will be performed with the Lixelle® column connected to upstream of the dialyzer in series on the routine HD circuit according to the description in the IFU. The dialyzer and the Kt/V urea in the conventional HD for each patient will be kept equal in Lixelle®-treatment. Since the maximum blood flow rate for Lixelle® is 250 ml/min, the dialysis time will be extended to achieve the target Kt/V urea. The study will not restrict the type of hemodialyzer and other conditions of HD as specified by the physician. However, any changes to the HD procedure should be recorded properly, and the Kt/V urea should be kept equal to that at the enrollment.
Study NCT02534051 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Care Pathway
Description: The clinical care pathway guides aspects of care specific to obese pregnant women:1st trimester: offer of testing for pre-existing diabetes with either 75g OGTT or 50g GCT, nuchal translucency ultrasound (u/s), calculation of body mass index, counselling about weight gain, advising about medical complications, screening for obstructive sleep apnea, and referral to Maternal-Fetal Medicine if history of bariatric surgery, 2nd trimester: offer of maternal-serum alpha fetal protein (spina bifida), anatomy u/s, and 50g GCT and 75g OGTT, 3rd trimester: offer of consultation with anesthesiology, u/s for growth \& well-being, counselling about birth risks, and discussion of breastfeeding.
Study NCT01267019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social cognitive training with in vivo augmentation
Description: 24 sessions of social cognitive training plus 6 sessions of in vivo exercises
Study NCT01267019 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: social cognitive training
Description: 30 sessions of social cognitive training without in vivo exercises
Study NCT01267019 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: non-social skills training
Description: 30 sessions of skills training that has no specific social content
Study NCT00468819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: In an open-label design, all patients will receive a total dose of 0.1 mmol/kg BW Gadovist 1.01 Days Injection
Study NCT02465905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: raw milk
Study NCT02465905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heated milk
Study NCT02265094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: EEG recordings during memory tests
Study NCT02295748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort
Description: Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.
Study NCT02612649 — intervention group
Intervention type: DRUG
Intervention: Ramosetron
Description: Oral
Study NCT03733418 — intervention group
Intervention type: DRUG
Intervention: 540,000 IU vitamin D3
Description: This intervention was administered as part of VIOLET parent study. A single dose of 540,000 IU vitamin D3 was administered within 2 hours of randomization time.
Study NCT04420702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI with DBSI analysis
Description: -The procedure will take approximately 1 hour of the participant's time
Study NCT03733418 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Placebo that matched the vitamin D3 color was provided.
Study NCT01082601 — intervention group
Intervention type: PROCEDURE
Intervention: Pulmonary Vein Isolation (PVI)
Description: Subjects with clinical indication for PVI, either paroxysmal or persistent AF failing medical management with rate or rhythm control medications.
Study NCT02265094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment
Description: patterns of eye gaze during cognitive tests
Study NCT03563768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-stop strategy group
Description: Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
Study NCT04061174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder stabilization exercises
Description: When participants are able to do the exercise 15 repetitions without difficulty, the exercise will be advanced by modifying or adding the weight.The exercises include chin tulk exercise, shoulder closed chain weight transfer, prone and iso-abdominal exercises, push-up exercise, lower trapezius muscle strengthening exercise, dead bug exercise, ball rolling on the wall, bench press with dumbbell and internal/external rotation (IR / ER) strengthening exercises
Study NCT04061174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Office exercises training
Description: Information will be given in a brochure that includes the appropriate chair height and work table, sitting position, distance between eyes and monitor, and table chair dimensions.approved and standardized office-based stretching and strengthening exercises will be given for workplaces
Study NCT03797911 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Active resistive capacitive monopolar radiofrequency with physiotherapeutic techniques and pain education
Description: Activated resistive capacitive monopolar radiofrequency is applied to the patient along with the conventional treatment of physiotherapeutic techniques and pain education.
Study NCT03797911 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Inactive resistive capacitive monopolar radiofrequency with physiotherapeutic techniques and pain education
Description: Disactivated resistive capacitive monopolar radiofrequency inactived is applied to the patient along with the conventional treatment of physiotherapeutic techniques and pain education.
Study NCT00929968 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00929968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAK694
Study NCT00929968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Study NCT02064374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg q12h
Description: Metformin will be supplied as 500 mg tablet to be administered orally.
Study NCT02064374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg q24h
Description: Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken once a day in the morning in Period 2 (Total daily dose 50 mg per day for Cohort 1 only)
Study NCT02064374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg q12h
Description: Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken 50 mg tablets every 12 hours in Period 2 (Total daily dose 100 mg per day for Cohort 2 only).
Study NCT02560636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab - Trial Treatment
Study NCT02560636 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy
Study NCT03633435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assisted home hemodialysis patients
Description: Arteriovenous fistula cannulation at the patient's home provided by a trained private nurse at each dialysis session with the rope-ladder technique, and connection to the Nxstage System One
Study NCT00901875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine + naloxone (Suboxone)
Description: Sublingual tablets
Study NCT00901875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine + naloxone (Suboxone)
Study NCT04423042 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab binds to both soluble and membrane-bound interleukin-6 receptors and has been shown to inhibit interleukin 6-mediated signalling.
Study NCT01898793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study NCT01898793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT04429633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Description: If GLS decreased less than 18% or LVEF decreased to 45-50% during the treatment of adjuvant trastuzumab, start candesartan medication.
Study NCT04912804 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: SF-12, GHQ-12 and HAQ
Study NCT03094949 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial Nephrectomy
Description: The renal capsule is cut in a monopolar fashion around the tumor. After the renal artery is clamped with a bulldog clamp, cold cutting by scissors into the renal parenchymal boundary of the tumor is performed with an optimal surgical margin (a few millimeters). After retrograde injection of diluted indigo carmine, continuous suturing of the opened collecting system and transection of the major vessels is performed with intracorporeal knot-tying. Parenchymal suturing is performed in a continuous fashion. The 20-30 cm length of thread is used, and a knot is made at the end of the thread. A large Hem-o-lok polymer clip (Weck Closure System, Research Triangle Park, NC) is attached on the proximal side of the knot. Before the thread is tightened or cinched, the parenchyma is sutured in a running fashion with three or four stitches without any bolster so that the renal bed is kept in its natural position during the suturing.
Study NCT03094949 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
Study NCT02880709 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Special diet
Description: Tate and energy content adjusted with spices to obtain maximal intake
Study NCT00075101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethosone
Description: 10 day study cycle: 5 day observation pre-steroid,5 day observation post-steroid
Study NCT01466907 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Secondary prevention, supportive counselling
Description: Patients' self-reports on Mobility, Self Care, Usual activities, Pain/Discomfort, Anxiety/Depression, Health Outcome were registered. Health problems were assessed. Secondary prevention was controlled by measuring blood pressure, Cholesterol levels, HbA1c, Weight to estimate nutritional status. Functional status was assessed. Supportive counselling was provided. Referral was sent to physician if medical interventions were needed.
Study NCT01466907 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care until one year follow-up
Description: No intervention three months after stroke. Assessment one year after stroke and comparison with the intervention group.
Study NCT00337155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (BAY88-8223)
Description: 3 doses of radium-223 at different dose levels, 25, 50 or 80 kBq/kg b.w.given as injection.
Study NCT00003786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irofulven
Study NCT02534467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: daily dose according to age for 8 weeks out of 16 weeks of assessment
Study NCT02534467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: daily dose according to age for 8 weeks out of 16 weeks of assessment
Study NCT02296671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study NCT02056223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Description: 15 mg/Kg every 6 hours for three days
Study NCT02056223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous ibuprofen
Description: 10 -5-5 mg/Kg once a day for three days
Study NCT02296671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT02296671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study NCT02296671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Study NCT02296671 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Germline genotyping analyses for TSER
Study NCT04469322 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mental Health DNA Insight Test (Pathway Genomics)
Description: Pharmacogenetic report based on the patients DNA profile at \~45 SNP markers covering 16 genes
Study NCT04469322 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Sham Test
Description: Names of 53 medications listed with use as directed
Study NCT03576794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide 20 mg
Description: During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
Study NCT03576794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Patients in both groups will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27.
Study NCT01898793 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Study NCT01898793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer cells
Study NCT03576794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Patients in both groups will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27.
Study NCT01002209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen treatment (HBO)
Description: HBO treatment will be given in a monoplace chamber and will start on first postoperative day (study day 1). The HBO group will be treated with 100% oxygen at 2.5 bar for 100 min with two 10 min airbrakes (without mask).~HBO treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO/placebo treatment and who have a clearly uncomplicated postoperative course will terminate HBO/placebo treatment on the day of discharge from hospital.
Study NCT01898793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Study NCT01898793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-803
Study NCT01069458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The high protein diet group and the low fat diet group
Description: The High Protein Diet Group was advised to have 25 energy percent from protein, 55 energy percent from fat, 20 energy percent from carbohydrate in the diet and the Low Fat Diet Group was advised to have 30 energy percent from fat, 20 energy percent from protein, 50 energy percent from carbohydrate in the diet.
Study NCT01898793 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood for correlative studies
Description: -Screening, Day 0 prior to CIML NK infusion, Day 1, Day 3, Day 7, Day 8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 60, Day 100, 6 months, 9 months, 12 months, and at disease relapse
Study NCT01069458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The high protein diet group and the low fat diet group
Description: The High Protein Diet Group was advised to have 25 energy percent from protein, 55 energy percent from fat, 20 energy percent from carbohydrate in the diet and the Low Fat Diet Group was advised to have 30 energy percent from fat, 20 energy percent from protein, 50 energy percent from carbohydrate in the diet.
Study NCT01638260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide once daily 1.8 mg injection subcutaneously, 26 weeks
Study NCT01638260 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NEAT
Description: Increasing NEAT by activating lifestyle interventions, combined with liraglutide once daily 1.8mg injections subcutaneously
Study NCT01827553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with gemcitabine or FOLFIRINOX
Description: According to medical recommendation, induction chemotherapy is performed with gemcitabine (3 cycles a 3 administrations, 1000 mg/m\^2/d)or FOLFIRINOX (6 cycles; 1 cycle: oxaliplatin 85 mg/m\^2 2 h infusion, folinic acid 400 mg/ m\^2 2h infusion completed after 30 min with irinotecan infusion 180 mg/m\^2 for 90 minutes, bolus application 5-FU 400 mg/m\^2 followed by 46h infusion of 5-FU 2400 mg/m\^2)
Study NCT01827553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction chemotherapy with gemcitabine or FOLFIRINOX
Description: According to medical recommendation, induction chemotherapy is performed with gemcitabine (3 cycles a 3 administrations, 1000 mg/m\^2/d)or FOLFIRINOX (6 cycles; 1 cycle: oxaliplatin 85 mg/m\^2 2 h infusion, folinic acid 400 mg/ m\^2 2h infusion completed after 30 min with irinotecan infusion 180 mg/m\^2 for 90 minutes, bolus application 5-FU 400 mg/m\^2 followed by 46h infusion of 5-FU 2400 mg/m\^2)